- Home
- GNW vs GH Comparison
GNW vs GH Comparison
Compare GNW & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNW
- GH
- Stock Information
- Founded
- GNW 1871
- GH 2011
- Country
- GNW United States
- GH United States
- Employees
- GNW N/A
- GH N/A
- Industry
- GNW Life Insurance
- GH Medical Specialities
- Sector
- GNW Finance
- GH Health Care
- Exchange
- GNW Nasdaq
- GH Nasdaq
- Market Cap
- GNW 3.0B
- GH 2.7B
- IPO Year
- GNW 2004
- GH 2018
- Fundamental
- Price
- GNW $7.34
- GH $29.11
- Analyst Decision
- GNW Hold
- GH Strong Buy
- Analyst Count
- GNW 1
- GH 16
- Target Price
- GNW $7.00
- GH $39.07
- AVG Volume (30 Days)
- GNW 2.7M
- GH 2.2M
- Earning Date
- GNW 11-06-2024
- GH 11-06-2024
- Dividend Yield
- GNW N/A
- GH N/A
- EPS Growth
- GNW N/A
- GH N/A
- EPS
- GNW 0.20
- GH N/A
- Revenue
- GNW $7,426,000,000.00
- GH $692,256,000.00
- Revenue This Year
- GNW N/A
- GH $31.00
- Revenue Next Year
- GNW N/A
- GH $17.55
- P/E Ratio
- GNW $34.03
- GH N/A
- Revenue Growth
- GNW N/A
- GH 29.20
- 52 Week Low
- GNW $5.67
- GH $15.81
- 52 Week High
- GNW $7.48
- GH $37.04
- Technical
- Relative Strength Index (RSI)
- GNW 62.40
- GH 65.43
- Support Level
- GNW $7.21
- GH $28.20
- Resistance Level
- GNW $7.48
- GH $32.26
- Average True Range (ATR)
- GNW 0.18
- GH 1.76
- MACD
- GNW 0.06
- GH 0.76
- Stochastic Oscillator
- GNW 85.86
- GH 63.35
About GNW Genworth Financial Inc
Genworth Financial is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. most of the revenue is generated by the Long-Term Care Insurance segment. The company earns most of its revenue in the United States.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.